Corticosteroids in Community Acquired Pneumonea

NCT ID: NCT01228110

Last Updated: 2010-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Low dose hydrocortisone IV in patients with CAP fastens recovery of pneumonia and prevents the development of sepsis related complications with a significant reduction in duration of mechanical ventilation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inclusion Criteria Minor criteria includes

* respiratory rate \> 30 bpm at admission;
* ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) \< 250;
* chest radiograph showing bilateral involvement or multilobar involvement;
* systolic blood pressure \< 90 mm Hg; or
* diastolic blood pressure \< 60 mm Hg. Major criteria includes
* Requirement of MV;
* Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;
* Requirement of vasopressors for more than 4 hours; or
* Serum creatinine 2 mg/dl or more.

Exclusion criteria:

* Children;
* Nosocomial pneumonia;
* Hospitalisation within the previous 14 days;
* Severe immunosuppression (chronic use of systemic steroids);
* Non-steroid immunosuppressive treatment or HIV);
* Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;
* Congestive heart failure (cerebrovascular stroke);
* Chronic renal or hepatic disease;
* Acute burn injury;
* Malignancy;
* Pregnancy; and
* Major gastrointestinal bleed within 3 months of the current hospitalization

Study Outcome The end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 \> 300 or ≥100 increase from study entry) and sepsis related organ failure assessment, (SOFA) score by day 8 and the development of delayed septic shock.

The adopted SOFA score (up to 6 points) was proposed by Vincent et al., \[21\]. The number of MV-free days was defined as the number of days after ventilation was discontinued up to study day 8. Shock was defined as requirement of vasopressors. ARDS was defined by consensus criteria.

All the patients were subjected to

1. Routine laboratory screen, including CBC, RBS, serum urea and creatinine, liver enzymes, serum billirubin and coagulation profiles;
2. Chest X ray on at least on admission and at day 8;
3. ABG at least once daily to detect PaO2:FIO2;
4. CRP daily from day 1 to 8 and
5. Evaluation of SOFA score daily

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community Acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Corticosteroid group

This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days

Group Type ACTIVE_COMPARATOR

Hydrocortison

Intervention Type DRUG

Placebo group

This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).

Group Type PLACEBO_COMPARATOR

Saline Solution

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrocortison

Intervention Type DRUG

Saline Solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Minor criteria included

* respiratory rate \> 30 bpm at admission;
* ratio of PaO2 to fraction of inspired oxygen (PaO2:FIO2 ) \< 250;
* chest radiograph showing bilateral involvement or multilobar involvement;
* systolic blood pressure \< 90 mm Hg; or
* diastolic blood pressure \< 60 mm Hg. Major criteria included
* Requirement of MV;
* Increase in the size of opacities on chest radiograph of 50% or more at 48 hours;
* Requirement of vasopressors for more than 4 hours; or
* Serum creatinine 2 mg/dl or more. 10

Exclusion Criteria

* Children;
* Nosocomial pneumonia;
* Hospitalisation within the previous 14 days;
* Severe immunosuppression (chronic use of systemic steroids);
* Non-steroid immunosuppressive treatment or HIV);
* Chronic chest disease; , tuberculosis, aspiration or obstructive pneumonia;
* Congestive heart failure (cerebrovascular stroke);
* Chronic renal or hepatic disease;
* Acute burn injury;
* Malignancy;
* Pregnancy; and
* Major gastrointestinal bleed within 3 months of the current hospitalization.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cairo University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06111972

Identifier Type: -

Identifier Source: org_study_id